Therapeutic Vaccine in Chronically HIV-1-Infected Patients: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial with HTI-TriMix

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting

(2019) Boris Julg et al.   Lancet HIV

Effective Suppression of HIV-1 Replication by Cytotoxic T Lymphocytes Specific for Pol Epitopes in Conserved Mosaic Vaccine Immunogens

(2019) Chengcheng Zou et al.   JOURNAL OF VIROLOGY

In-vitro viral suppressive capacity correlates with immune checkpoint marker expression on peripheral CD8+ T cells in treated HIV-positive patients

(2019) Pieter Pannus et al.   AIDS

Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study)

(2019) Antonella Castagna et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

(2019) Alison J Rodger et al.   LANCET

Altered differentiation is central to HIV-specific CD4+ T cell dysfunction in progressive disease

(2019) Antigoni Morou et al.   NATURE IMMUNOLOGY

iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy

(2019) Wesley de Jong et al.   Trials

A Comparison of Plasmid DNA and mRNA as Vaccine Technologies

(2019) Liu   Vaccines

Virological outcome measures during analytical treatment interruptions in chronic HIV-1 infected patients

(2019) Csaba Fehér et al.   Open Forum Infectious Diseases

Immune Checkpoints as the Immune System Regulators and Potential Biomarkers in HIV-1 Infection

(2018) Maike Sperk et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector

(2018) Lindsey R Baden et al.   JOURNAL OF INFECTIOUS DISEASES

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)

(2018) Dan H Barouch et al.   LANCET

Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals

(2018) Katherine E. Clarridge et al.   PLoS Pathogens

Transcriptomics and Targeted Proteomics Analysis to Gain Insights Into the Immune-control Mechanisms of HIV-1 Infected Elite Controllers

(2018) Wang Zhang et al.   EBioMedicine

Phase I clinical trial of an intranodally administered mRNA based therapeutic vaccine against HIV-1 infection

(2018) Lorna Leal et al.   AIDS

RNA is taking its Toll: Impact of RNA‐specific Toll‐like receptors on health and disease

(2018) Tim Vierbuchen et al.   ALLERGY

New challenges in therapeutic vaccines against HIV infection

(2017) Lorna Leal et al.   Expert Review of Vaccines

Sensitive quantification of the HIV-1 reservoir in gut-associated lymphoid tissue

(2017) Sara Morón-López et al.   PLoS One

Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix)

(2016) Alberto C. Guardo et al.   AIDS

International AIDS Society global scientific strategy: towards an HIV cure 2016

(2016) Steven G Deeks et al.   NATURE MEDICINE

Therapeutic vaccines and immunological intervention in HIV infection

(2016) Giuseppe Pantaleo et al.   Current Opinion in HIV and AIDS

The need for treatment interruption studies and biomarker identification in the search for an HIV cure

(2015) Jonathan Z. Li et al.   AIDS

Establishment and Replenishment of the Viral Reservoir in Perinatally HIV-1-infected Children Initiating Very Early Antiretroviral Therapy

(2015) Marta Martínez-Bonet et al.   CLINICAL INFECTIOUS DISEASES

A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques

(2015) Beatriz Mothe et al.   Journal of Translational Medicine

Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells

(2015) S. Van Lint et al.   Cancer Immunology Research

Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula

(2014) Sandra Van Lint et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Altered Response Hierarchy and Increased T-Cell Breadth upon HIV-1 Conserved Element DNA Vaccination in Macaques

(2014) Viraj Kulkarni et al.   PLoS One

Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1

(2013) Nicola Borthwick et al.   MOLECULAR THERAPY

Preclinical Evaluation of TriMix and Antigen mRNA-Based Antitumor Therapy

(2012) S. Van Lint et al.   CANCER RESEARCH

CTL Responses of High Functional Avidity and Broad Variant Cross-Reactivity Are Associated with HIV Control

(2012) Beatriz Mothe et al.   PLoS One

Definition of the viral targets of protective HIV-1-specific T cell responses

(2011) Beatriz Mothe et al.   Journal of Translational Medicine

Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients

(2010) Susanne M Rittig et al.   MOLECULAR THERAPY

The mechanism of eukaryotic translation initiation and principles of its regulation

(2010) Richard J. Jackson et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients

(2009) Benjamin Weide et al.   JOURNAL OF IMMUNOTHERAPY

Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA

(2008) Benjamin Weide et al.   JOURNAL OF IMMUNOTHERAPY